CorEvitas brings Thermo Fisher Scientific registries that gather data about how approved therapies are working in the real world. The acquisition will complement PPD, the contract research organization that Thermo Fisher purchased in 2021.
UnitedHealth Group's Optum is acquiring Amedisys through an all-cash transaction for $101 per share, the companies announced Monday. The move represents a continuing shift to home-based care, several experts said.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
In the 12 months leading up to May 15, health services deal volumes decreased just 4% from the year prior, a new report from PwC found. There was a 15% decrease in deal values.
Eli Lilly’s acquisition of Dice Therapeutics comes eight months after the biotech reported positive data from a Phase 1 study in psoriasis. Dice develops oral small molecule drugs intended to offer alternatives to biologic drugs that are injected or infused.
Healthcare dealmakers must prepare for a new law and a recently-introduced bill in the California Senate, both of which aim to increase oversight in the healthcare M&A space. This is a legislative trend other states are beginning to participate in too — such as New York, Massachusetts and Connecticut.
Novartis is acquiring Chinook Therapeutics in a $3.2 billion deal that brings two late-stage drug candidates for a rare kidney disorder. The Novartis drug pipeline already has a molecule in late-stage development for the same kidney disease, which could raise questions from antitrust regulators.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The Federal Trade Commission is suing to stop Amgen’s acquisition of Horizon Therapeutics. But rather than claiming product overlap, the agency contends Amgen will use its influence to keep at bay competition for Horizon’s products.
Kaiser Permanente announced that it expects to acquire Pennsylvania-based Geisinger Health. Kaiser’s move is part of a larger plan — Geisinger will be the first health system to join Risant Health, a new company Kaiser launched to operate nonprofit health systems under value-based care models. Kaiser said it expects to invest $5 billion in Risant and fold five or six health systems into the company over the next five years.
Adaptimmune and TCR2 Therapeutics have complementary technologies and an aligned strategy of developing cell therapies for solid tumors, but this marriage is preceded by divorce. Before consummating the TCR2 deal, Adaptimmune ended an alliance with a larger pharmaceutical company.
Rumors of the deal first surfaced in January, with some dismissing the idea. Several experts say the deal makes sense for CVS Health, as it looks to expand into primary and value-based senior care.
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
Sun Pharmaceuticals is acquiring Concert Pharmaceuticals, a biotech whose lead program has positive data from two late-stage clinical trials in alopecia areata. The deal gives Sun Pharma a drug candidate that could match up against hair loss drugs from two big pharmaceutical companies.
CVS Health announced investments this week in Carbon Health, Monogram Health and Array Behavioral Care. There have also been rumors that the company is exploring a $10 billion deal with primary care company Oak Street Health.
LeanTaaS acquired healthcare automation company Hospital IQ. The two companies made the deal because their products complement each other — Hospital IQ provides staff optimization solutions, while LeanTaaS makes software to optimize capacity for operating rooms, infusion centers and inpatient beds.
Whether it was Amazon's buy of One Medical or CVS Health's acquisition of Signify Health, retailers made waves in healthcare this year. Across all of the deals, it's clear that expanding access to medical services is the key goal, experts said. And this is only the beginning.
Some industry experts seem skeptical of the rumored deal between Amwell and Talkspace, while others disagree. The rumored purchasing price is $200 million at about $1.50 per share.